{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T03:06:49Z","timestamp":1781320009849,"version":"3.54.1"},"reference-count":83,"publisher":"Informa UK Limited","issue":"sup2","license":[{"start":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T00:00:00Z","timestamp":1603497600000},"content-version":"unspecified","delay-in-days":46,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Novo Nordisk Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Postgraduate Medicine"],"published-print":{"date-parts":[[2020,10,16]]},"DOI":"10.1080\/00325481.2020.1798162","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T10:56:07Z","timestamp":1597920967000},"page":"48-60","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":22,"title":["Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?"],"prefix":"10.1080","volume":"132","author":[{"given":"Stephen A.","family":"Brunton","sequence":"first","affiliation":[{"name":"Touro University California, Vallejo, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofri","family":"Mosenzon","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel"},{"name":"Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0796-0496","authenticated-orcid":false,"given":"Eugene E.","family":"Wright Jr","sequence":"additional","affiliation":[{"name":"Charlotte Area Health Education Center, Charlotte, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,9,8]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0749"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30192-5"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30194-9"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31271-1"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0883"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.2942"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0898"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118"},{"key":"cit0009","unstructured":"Rybelsus\u00ae (semaglutide) prescribing information [updated Jan 2020; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213182s000,213051s001lbl.pdf"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-S011"},{"issue":"1","key":"cit0011","first-page":"50","volume":"62","author":"Dahl K","year":"2019","journal-title":"Diabetologia"},{"key":"cit0012","unstructured":"Novo Nordisk. Rybelsus\u00ae (oral semaglutide) approved for the treatment of adults with type 2 diabetes in the EU. 2020 [cited 2020 May 25] Available from: https:\/\/www.novonordisk.com\/media\/news-details.2277630.html"},{"key":"cit0013","unstructured":"Bydureon\u00ae (exenatide extended-release) prescribing information [updated Feb 2020; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/022200s030lbl.pdf"},{"key":"cit0014","unstructured":"Victoza\u00ae (liraglutide) prescribing information [updated Jun 2019; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022341s031lbl.pdf"},{"key":"cit0015","unstructured":"Adlyxin\u00ae (lixisenatide) prescribing information [updated Jan 2019; cited 2020 May 25]. Available from: http:\/\/products.sanofi.us\/Adlyxin\/Adlyxin.pdf"},{"key":"cit0016","unstructured":"Byetta\u00ae (exenatide) prescribing information [updated Feb 2020; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021773s043lbl.pdf"},{"key":"cit0017","unstructured":"Ozempic\u00ae (semaglutide) prescribing information [updated Jan 2020; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209637s003lbl.pdf"},{"key":"cit0018","unstructured":"Trulicity\u00ae (dulaglutide) prescribing information [updated Feb 2020; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125469s033lbl.pdf"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.4158\/CS-2019-0472"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-S009"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz486"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13028"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32261-X"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2020.1798638"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2020.1798127"},{"key":"cit0029","unstructured":"U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. National diabetes statistics report 2020: estimates of diabetes and its burden in the United States. [cited 2020 May 25]. Available from: https:\/\/www.cdc.gov\/diabetes\/pdfs\/data\/statistics\/national-diabetes-statistics-report.pdf"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-S008"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13804"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0566"},{"key":"cit0033","unstructured":"Saxenda\u00ae (liraglutide) prescribing information [updated Oct 2018; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/206321s007lbl.pdf"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-02804"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2016.40.6.423"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2007.02341.x"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00800209"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0649-2"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.2337\/cd18-0034"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.11.015"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.86a.17107"},{"key":"cit0042","doi-asserted-by":"crossref","unstructured":"Brunton SA, Wysham CH. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. Postgrad Med. 2020;132(S2):3\u201314.","DOI":"10.1080\/00325481.2020.1798099"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0199-z"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-0615-5"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1421146"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S71923"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-019-00826-0"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0819-5"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.05.009"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.14752"},{"key":"cit0051","unstructured":"Farxiga\u00ae (dapagliflozin) prescribing information [updated Jan 2020; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/202293s022lbl.pdf"},{"key":"cit0052","unstructured":"Jardiance\u00ae (empagliflozin) prescribing information [updated Jan 2020; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/204629s023lbl.pdf"},{"key":"cit0053","unstructured":"Invokana\u00ae (canagliflozin) prescribing information [updated Jan 2020; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/204042s036lbl.pdf"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1131"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2020.1800286"},{"key":"cit0056","unstructured":"Clinicaltrials.gov. A heart disease study of semaglutide in patients with type 2 diabetes (SOUL). Trial ID NCT03914326. [cited 2020 May 25]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03914326"},{"key":"cit0057","doi-asserted-by":"crossref","unstructured":"Aroda VR, Bauer R, Herts CL, et al. Efficacy and safety of oral semaglutide by baseline age in the PIONEER clinical trial program. Diabetes. 2020;69(Suppl 1):932-P.","DOI":"10.2337\/db20-932-P"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-S012"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.31.4.148"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009843"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30172-6"},{"issue":"2","key":"cit0062","first-page":"e4127","volume":"11","author":"Olson E","year":"2019","journal-title":"Cureus"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2010.223"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-02055-z"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-016-0389-8"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1534365"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1144"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2019.05.005"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0030"},{"issue":"1","key":"cit0070","first-page":"49","volume":"62","author":"Haluz\u00edk M","year":"2019","journal-title":"Diabetologia"},{"issue":"1","key":"cit0071","first-page":"51","volume":"62","author":"Meier JJ","year":"2019","journal-title":"Diabetologia"},{"key":"cit0072","volume-title":"Presented at the American Diabetes Association","author":"Maarbjerg SJ","year":"2017"},{"issue":"1","key":"cit0073","first-page":"SAT","volume":"3","author":"Hauge C","year":"2019","journal-title":"J Endocr Soc"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2014.0028"},{"issue":"1","key":"cit0075","first-page":"S361","volume":"60","author":"Connor A","year":"2017","journal-title":"Diabetologia"},{"key":"cit0076","first-page":"45","volume":"21","author":"Milne N","year":"2019","journal-title":"Diabetes Primary Care"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2018.1488965"},{"issue":"1","key":"cit0078","first-page":"714","volume":"61","author":"B\u00e6kdal TA","year":"2018","journal-title":"Diabetologia"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00756-2"},{"issue":"1","key":"cit0080","first-page":"713","volume":"61","author":"Jordy AB","year":"2018","journal-title":"Diabetologia"},{"key":"cit0081","unstructured":"Levoxyl\u00ae (levothyroxine sodium) prescribing information [updated Nov 2018; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021301s038lbl.pdf"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2010.03085.x"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-0669-4"}],"container-title":["Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/00325481.2020.1798162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T17:15:38Z","timestamp":1620580538000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/00325481.2020.1798162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,8]]},"references-count":83,"journal-issue":{"issue":"sup2","published-print":{"date-parts":[[2020,10,16]]}},"alternative-id":["10.1080\/00325481.2020.1798162"],"URL":"https:\/\/doi.org\/10.1080\/00325481.2020.1798162","relation":{},"ISSN":["0032-5481","1941-9260"],"issn-type":[{"value":"0032-5481","type":"print"},{"value":"1941-9260","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-06-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}